1,525 results on '"Davidson, Michael H."'
Search Results
102. Comparison of the Safety and Efficacy of a Combination Tablet of Niacin Extended Release and Simvastatin vs Simvastatin Monotherapy in Patients With Increased Non–HDL Cholesterol (from the SEACOAST I Study)
103. Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy
104. Niacin Use and Cutaneous Flushing: Mechanisms and Strategies for Prevention
105. Usefulness of Increased Skin Cholesterol to Identify Individuals at Increased Cardiovascular Risk (from the Predictor of Advanced Subclinical Atherosclerosis Study)
106. A 50-Week Extension Study on the Safety and Efficacy of Colesevelam in Adults with Primary Hypercholesterolemia
107. Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus: Results of a Pooled Subgroup Analysis from Three Randomized, Controlled, Double-Blind Trials
108. Lp-PLA2: A New Target for Statin Therapy
109. Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia
110. RE: Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial
111. Flushing ASsessment Tool (FAST©): Psychometric Properties of a New Measure Assessing Flushing Symptoms and Clinical Impact of Niacin Therapy
112. Novel nonstatin strategies to lower low-density lipoprotein cholesterol
113. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia
114. Atherosclerosis surrogate imaging trials come of age: For better or for worse?
115. The use of high-sensitivity assays for C-reactive protein in clinical practice
116. Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins: Study Design and Rationale of a Phase III Clinical Programme
117. Retrospective Comparison of the Effectiveness of a Fenofibrate 145 mg Formulation Compared with the Standard 160 mg Tablet
118. The clinical black, white, and gray lessons
119. Long-Term Safety and Efficacy of a Combination of Niacin Extended Release and Simvastatin in Patients with Dyslipidemia: The OCEANS Study
120. Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid
121. DYSLIPIDAEMIA: PCSK9 antibodies: a dividend of the genomics revolution
122. Rosuvastatin in Elderly Patients
123. Lipid sub-fractionation predicts worsening myocardial perfusion reserve in patients with low-density lipoprotein less than 100mg/dL: a regadenoson dardiac magnetic resonance study
124. Ethnic differences in achievement of cholesterol treatment goals: Results from the national cholesterol education program evaluation project utilizing novel E-technology II
125. Safety of Aggressive Lipid Management
126. Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults
127. Therapy to Manage Low High-Density Lipoprotein Cholesterol and Elevated Triglycerides
128. Contributors
129. Titration patterns with rosuvastatin as compared with other statins in clinical practice: A retrospective observational cohort study using an electronic medical record database
130. Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study
131. High-Density Lipoprotein Metabolism: Potential Therapeutic Targets
132. Safety Considerations with Fibrate Therapy
133. Global Risk Management in Patients with Type 2 Diabetes Mellitus
134. Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: Results of a national survey
135. Effect of ACAT inhibition on the progression of coronary artherosclerosis
136. Biologic therapies for dyslipidemia
137. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk
138. Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
139. Fast Facts: Familial Chylomicronemia Syndrome : Raising Awareness of a Rare Genetic Disease
140. Newer pharmaceutical agents to treat lipid disorders
141. Niacin: A powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events
142. Combination lipid-lowering therapy in diabetes
143. Efficacy of over-the-counter nutritional supplements
144. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS’ COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2013 CONSENSUS STATEMENT - EXECUTIVE SUMMARY
145. Diagnosis and treatment of familial hypercholesterolaemia
146. Management of Hypercholesterolaemia in Postmenopausal Women
147. Contributors
148. Low-Density Lipoprotein Cholesterol
149. Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels on a Background of Atorvastatin
150. Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.